Table 1

Patient baseline and 1- and 3-year characteristics by radiographs and HAQ-DI score available at 3 years

Patient characteristicsAll patients,
n=625
Patients with radiographs
at 3 years,
n=496
Patients with HAQ-DI score at 3 years, n=535
No. observedNo. observedNo. observed
Baseline characteristics
 Age, years, mean (SD)62548.5 (12.1)49648.8 (11.9)53548.6 (12.0)
 Gender, female, number (%)625491 (78.6)496391 (78.8)535420 (78.5)
 Symptom/disease duration*, months, mean (SD)6257.3 (8.6)4967.6 (9.0)5357.6 (9.0)
 RF presence, number (%)625334 (53.4)496262 (52.8)535288 (53.8)
 ACPA
  ▸ Absence, number (%)625340 (54.4)496265 (53.4)535278. (52.0)
  ▸ Low titres, number (%)62547 (7.5)49640 (8.1)53543 (8.0)
  ▸ High titres, number (%)625238 (38.1)496191 (38.5)535214 (40.0)
 Smokers, number (%)625301 (48.2)496238 (48.0)535255 (47.7)
 mTSS, mean (SD)5945.3 (7.6)4965.6 (7.8)5175.6 (7.9)
 HAQ-DI, mean (SD)6251.0 (0.7)4961.0 (0.7)5351.0 (0.7)
 Patients with erosive disease, number (%)594215 (36.2)496175 (35.3)517182 (34)
1-year characteristics
 SDAI remission, number (%)625121 (19.4)49694 (19.0)535103 (19.3)
 SDAI LDA, number (%)625223 (35.7)496178 (35.9)535198 (37.0)
 SDAI MDA or HDA number (%)625281 (45.0)496224 (45.2)535234 (43.7)
 Glucocorticoids use, number (%)625292 (46.7)496231 (46.6)535251 (46.9)
 Cumulative glucocorticoids intake, mg, mean (SD)6211058 (1407)4941035 (1384)5331053 (1385)
 DMARDs use, number (%)625516 (82.6)496411 (82.9)535445 (83.2)
 Delay before first DMARDs intake†, months, mean (SD)5381.1 (1.9)4301.1 (1.9)4641.1 (1.9)
 Biological DMARDs use, number (%)62542 (6.7)49635 (7.1)53538 (7.1)
3-year characteristics
 mTSS, mean (SD)51114.3 (14.9)49614.3 (14.9)50714.3 (14.9)
 HAQ-DI, mean (SD)5350.5 (0.6)4920.5 (0.6)5350.5 (0.6)
 Glucocorticoids use, number (%)539219 (35.0)493199 (40.1)535217 (40.6)
 DMARDs use, number (%)539403 (74.8)493367 (74.4)535399 (74.6)
 Biological DMARDs use, number (%)53975 (13.9)49370 (14.1)53575 (14.0)
  • *Difference between onset of first joint pain and inclusion in the ESPOIR cohort.

  • †Difference between the date of inclusion in ESPOIR cohort and the first DMARDs intake.

  • p<0.05 values are shown in bold.

  • ACPA, anticitrullinated peptides antibodies, no, low and high titres of ACPA by anti-CCP2 antibodies definition was <50, 50–150 and >150 U/mL, respectively; DMARDs: disease-modifying antirheumatic drugs; HAQ-DI, Health Assessment Questionnaire Disability Index; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity; mTSS, modified Sharp–van der Heijde total score; RF, rheumatoid factor; SDAI, Simple Disease Activity Index.